Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the efficacy and safety of different doses of ruxolitinib as
a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis(HLH).